Kelly Murata

Cooley represented Sight Sciences (listed as SGHT on Nasdaq), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, which received a jury trial win on April 26, 2024, against its competitors – Alcon, Alcon Vision and Alcon Research (collectively known as Alcon) and Ivantis – in the US District Court for the District of Delaware.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.